CN110279729B - Application of Nitraria tangutorum bobr extract in preparation of food, medicine or health-care product for inhibiting activities of sucrase and maltase - Google Patents
Application of Nitraria tangutorum bobr extract in preparation of food, medicine or health-care product for inhibiting activities of sucrase and maltase Download PDFInfo
- Publication number
- CN110279729B CN110279729B CN201910665113.6A CN201910665113A CN110279729B CN 110279729 B CN110279729 B CN 110279729B CN 201910665113 A CN201910665113 A CN 201910665113A CN 110279729 B CN110279729 B CN 110279729B
- Authority
- CN
- China
- Prior art keywords
- extract
- nitraria tangutorum
- sucrase
- nitraria
- maltase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001104824 Nitraria tangutorum Species 0.000 title claims abstract description 63
- 239000000284 extract Substances 0.000 title claims abstract description 63
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 43
- 108010028144 alpha-Glucosidases Proteins 0.000 title claims abstract description 35
- 102400000472 Sucrase Human genes 0.000 title claims abstract description 30
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 title claims abstract description 29
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 title claims abstract description 29
- 235000011073 invertase Nutrition 0.000 title claims abstract description 29
- 102000016679 alpha-Glucosidases Human genes 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 235000013305 food Nutrition 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000008280 blood Substances 0.000 claims abstract description 24
- 210000004369 blood Anatomy 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 23
- 230000000291 postprandial effect Effects 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 239000008103 glucose Substances 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 19
- 239000000047 product Substances 0.000 claims description 15
- 238000002137 ultrasound extraction Methods 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 8
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 7
- 239000000469 ethanolic extract Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- -1 patch Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 22
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 17
- 241000196324 Embryophyta Species 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 229940126673 western medicines Drugs 0.000 abstract description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 22
- 229960002632 acarbose Drugs 0.000 description 20
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 20
- 241000159206 Nitraria Species 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 102000004139 alpha-Amylases Human genes 0.000 description 8
- 108090000637 alpha-Amylases Proteins 0.000 description 8
- 229940024171 alpha-amylase Drugs 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 239000006286 aqueous extract Substances 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- 244000265913 Crataegus laevigata Species 0.000 description 4
- 235000013175 Crataegus laevigata Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 3
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960001110 miglitol Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 201000009104 prediabetes syndrome Diseases 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960001729 voglibose Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000587240 Cynanchum Species 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 102000001746 Pancreatic alpha-Amylases Human genes 0.000 description 1
- 108010029785 Pancreatic alpha-Amylases Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011802 pulverized particle Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides an application of Nitraria tangutorum bobr extract in preparing foods, medicines or health-care products for inhibiting activities of sucrase and maltase, relates to the technical field of biology, and provides an application of Nitraria tangutorum bobr extract in preparing foods, medicines or health-care products for inhibiting activities of sucrase and maltase. The tangut Nitraria tangutorum alcohol extract is a pure natural and plant-derived extract, has an inhibiting effect on both the activities of sucrase and maltase, and is low in preparation cost and small in side effect compared with western medicines. Experiments show that the tangut Nitraria tangutorum alcohol extract provided by the invention can effectively reduce the postprandial blood sugar of normal mice and diabetic mice.
Description
Technical Field
The invention relates to the technical field of biology, in particular to application of a Nitraria tangutorum bobr extract in preparation of foods, medicines or health-care products for inhibiting activities of sucrase and maltase.
Background
Diabetes Mellitus (DM), a chronic metabolic disease characterized by persistent hyperglycemia caused by the interaction of genetic and environmental factors, has become one of the major chronic non-infectious diseases affecting the health of the population worldwide, and its prevalence has increased year by year. The International Diabetes Federation (IDF) estimates that 4.25 million people worldwide have Diabetes, a figure that is expected to approach approximately 7 million by 2045 years. Persistent hyperglycemia is the major phenotype of diabetes and leads to serious diabetic complications over time, including coronary artery disease, stroke, peripheral artery disease, retinopathy, nephropathy, and neuropathy. Modern pharmacological studies have shown that almost all type ii diabetes mellitus passes through the Impaired Glucose Tolerance (IGT) stage, and the main clinical feature of IGT is postprandial hyperglycemia. Postprandial hyperglycemia is considered to be an important factor causing macrovascular complications and microvascular complications in diabetic patients, and these complications are a major cause of increased mortality from diabetes. The use of alpha-glucosidase inhibitors to inhibit the activity of human amylase and human small intestine alpha-glucosidase, to maintain Postprandial Blood Glucose (PBG) levels close to normal, is an important approach to controlling blood glucose excursions and to treat and prevent diabetes and its complications.
At present, alpha-glucosidase inhibitors applied in the DM medicament market in China mainly comprise acarbose (acarbose), voglibose (voglibose) and miglitol (miglitol), and the pharmaceutical activity of reducing postprandial hyperglycemia can be realized by inhibiting the activity of glycosidase in vivo, reducing the degradation of starch and oligosaccharide, reducing the generation of glucose and delaying the absorption of glucose into blood. Acarbose has the function of reducing blood sugar mainly by inhibiting the activities of amylase and sucrase and inhibiting the decomposition of starch and sucrose. Miglitol and voglibose mainly play a role in reducing the sugar level by inhibiting the activity of sucrase and maltosidase and reducing the further hydrolysis of sucrose and maltose. However, they are expensive, and are highly stressed in terms of economy for most of the diabetics taking the medicine for a long time, and have the side effects of diarrhea, abdominal colic, flatulence, vomiting and the like. Therefore, from natural plant resources, finding and discovering natural components for inhibiting alpha-glucosidase and potential drug-forming compounds thereof, and developing safe and efficient natural hypoglycemic drugs have important academic value and social significance.
Tangut white thorn (Nitraria tangutorum Bobr.) is a group-building deciduous shrub of the genus Nitraria (Zygophylceae), is a wild plant with homology of medicine and food, and has high economic, ecological and medicinal values. The record of 'materia medica shiyi' records 'nazi (name of nitraria), sweet and flat taste, no toxicity, qi tonifying and weight reducing (weight reducing), no hunger after long-term use and muscle and bone strengthening'. In folk, Tanggute Nitraria Tangutica is often used to treat weakness of the spleen and stomach, dyspepsia, neurasthenia, hyperglycemia, dizziness, cold, agalactia, etc. At present, scientific research on Tangut nitraria is relatively lacked at home and abroad, and scientific understanding and reasonable utilization of Tangut nitraria are still in the beginning stage. Soxhlet et al reported that the extract of Nitraria tangutorum bobr has activity in treating type II diabetes (soxhlet, Wanwang Cynanchum. research on hypoglycemic action of Nitraria tangutorum bobr fruit [ J. food science. 2004,25, 164-. There is no report that the crude extract of Nitraria tangutorum has inhibitory effect on sucrase and maltose activity.
Disclosure of Invention
The invention provides an application of Tangut Nitraria tangutorum extract in preparing foods, medicines or health products for inhibiting activities of sucrase and maltase, aiming at overcoming the defects of high price and large side effect of the existing hypoglycemic drugs.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides application of a tangut Nitraria tangutorum alcohol extract in preparation of foods, medicines or health-care products for inhibiting activities of sucrase and maltase.
Preferably, the preparation method of the Nitraria tangutorum bobr extract comprises the following steps:
pulverizing Nitraria tangutorum bobr, extracting with ethanol water solution with volume concentration of more than 90%, performing solid-liquid separation, removing precipitate, and drying the liquid part to obtain Nitraria tangutorum bobr ethanol extract.
Preferably, the ratio of the mass of the tangut white thorn powder obtained after crushing to the volume of the ethanol water solution is 1 g: 5-10 ml.
Preferably, the extraction is ultrasonic extraction.
Preferably, the temperature of ultrasonic extraction is 30-45 ℃, the time of ultrasonic extraction is 1.5-3.5 h, and the frequency of ultrasonic extraction is 15-35 kHz.
Preferably, the number of times of ultrasonic extraction is 1-3.
Preferably, the Nitraria tangutorum extract reduces postprandial blood glucose by inhibiting sucrase and maltase activity.
Preferably, the dosage form of the food, the medicine or the health care product comprises tablets, oral liquid, granules, injection, patches, paste, powder, suppositories and capsules.
Preferably, in the food, the medicine or the health-care product, the mass percentage concentration of the Nitraria tangutorum bobr extract is 0.1-99.9%.
Preferably, the food, the medicine or the health-care product also comprises auxiliary materials.
Compared with the prior art, the invention has the beneficial effects that:
(1) the invention provides a water extract or alcohol extract of Nitraria tangutorum bobr in the preparation of a composition for inhibiting activity of sucrase and maltase, wherein the Nitraria tangutorum bobr alcohol extract is a pure natural and plant-derived extract, and has low preparation cost and small side effect compared with western medicines.
(2) Experiments show that the tangut Nitraria tangutorum alcohol extract provided by the invention can effectively reduce the postprandial blood sugar of normal mice and diabetic mice.
(3) Experiments show that the Nitraria tangutorum alcohol extract provided by the invention has an inhibiting effect on both sucrase and maltase activity, and further can significantly reduce postprandial blood glucose level.
Drawings
FIG. 1 is a graph of the postprandial blood glucose lowering effect of Nitraria tangutorum alcohol extract and acarbose of the present invention; wherein, fig. 1A is the influence of the tangut white stinging alcohol extract and the acarbose on the postprandial blood sugar of normal mice, and fig. 1B is the influence of the tangut white stinging alcohol extract and the acarbose on the postprandial blood sugar of diabetic mice; FIG. 1C is a graph showing the visual analysis of the effect of Nitraria tangutorum alcohol extract and acarbose on the postprandial blood glucose of normal mice; FIG. 1D is a graph showing the visual analysis of the effect of Nitraria tangutorum alcohol extract and acarbose on postprandial blood glucose in diabetic mice;
FIG. 2 is a graph showing the inhibitory activity of Nitraria tangutorum alcohol extract and acarbose alpha-amylase in the present invention; wherein the left panel represents the positive drug acarbose amylase inhibitory activity IC50The right panel represents the amylase inhibiting activity IC of the Nitraria tangutorum aqueous extract50A value;
FIG. 3 is a graph showing the inhibitory activity of an alcohol extract of Nitraria tangutorum and acarbose sucrase according to the present invention; wherein the left panel represents the positive drug acarbose sucrase inhibitory activity IC50The right graph represents the sucrase inhibitory activity IC of the Nitraria tangutorum aqueous extract50A value;
FIG. 4 is a graph showing the inhibitory activity of Nitraria tangutorum extract and acarbose maltase; wherein the left panel represents the positive drug acarbose maltase inhibitory activity IC50The right panel represents the maltase inhibitory activity IC of the Nitraria tangutorum aqueous extract50The value is obtained.
Detailed Description
The invention provides application of an alcohol extract of Nitraria tangutorum bobr in preparation of food, medicine or health care product for inhibiting activities of sucrase and maltase, wherein the alcohol extract of Nitraria tangutorum bobr is a water extract or an alcohol extract of Nitraria tangutorum bobr.
Specifically, the preparation method of the tangut Nitraria tangutorum alcohol extract comprises the following steps:
pulverizing Nitraria tangutorum bobr, extracting with ethanol water solution with volume concentration of more than 90%, performing solid-liquid separation, removing precipitate, and drying the liquid part to obtain Nitraria tangutorum bobr ethanol extract.
In the present invention, the pulverized particle size is preferably 80 to 150 mesh, and more preferably 100 mesh.
In the present invention, the ratio of the mass of the tangut white thorn powder obtained after pulverization to the volume of the ethanol aqueous solution or water is preferably 1 g: 5-10 ml, more preferably 1 g: 6-8 ml. In the present invention, the volume concentration of the ethanol aqueous solution is preferably 95%.
In the present invention, the extraction is preferably ultrasonic extraction, which is faster, but other extraction methods, such as heat extraction, may also be used. In the invention, the temperature of ultrasonic extraction is preferably 30-45 ℃, and more preferably 40 ℃; the ultrasonic extraction time is preferably 1.5-3.5 h, and more preferably 2-3 h; the frequency of ultrasonic extraction is preferably 15-35 kHz, and more preferably 20 kHz. In the invention, the number of times of ultrasonic extraction is preferably 1-3.
The method of the solid-liquid separation in the present invention is not particularly limited, and a solid-liquid separation method known in the art, such as centrifugation or filtration, may be used.
In the invention, the Nitraria tangutorum alcohol extract can effectively reduce the blood sugar content in vivo by inhibiting the activity of sucrase and maltase.
In the present invention, the dosage form of the hypoglycemic food, medicine or health product includes, but is not limited to, tablets, oral liquids, granules, injections, patches, pastes, powders, suppositories and capsules. In the food, the medicine or the health-care product, the mass percentage concentration of the Nitraria tangutorum bobr extract is preferably 0.1-99.9%, and more preferably 1-95%. In the invention, the food, the medicine or the health-care product preferably also comprises auxiliary materials, and the type and the dosage of the specific auxiliary materials are not specially limited, and the auxiliary materials can be selected and determined according to different dosage forms.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
Crushing the dried Tangut bur to 100 meshes to obtain Tangut bur powder; mixing Tangut Nitraria Tangutica powder with 95% ethanol water solution according to the weight ratio of 1 g: mixing 6ml, ultrasonic extracting at 40 deg.C and 20kHz for 2 times, each time for 2 hr, and mixing the supernatants to obtain Tangut Nitraria extract.
Example 2
Crushing the dried Tangut bur to 80 meshes to obtain Tangut bur powder; mixing Tangut Nitraria Tangutica powder with 90% ethanol water solution according to the weight ratio of 1 g: mixing 5ml, ultrasonic extracting at 39 deg.C and 18kHz for 3 times, each for 2.5 hr, and mixing the supernatants to obtain Tangut Nitraria water extract.
Comparative example 1
Crushing the dried Tangut bur to 120 meshes to obtain Tangut bur powder; mixing Tangut Nitraria Tangutica powder with water according to the weight ratio of 1 g: mixing 10ml, ultrasonic extracting at 40 deg.C and 20kHz for 2 times, each time for 2 hr, and mixing the supernatants to obtain Tangut Nitraria water extract.
Example 3
1. Experimental material and experimental instrument
Experimental materials:
the tested drugs are: the aqueous extract of Nitraria tangutorum prepared in comparative example 1, and the alcohol extract of Nitraria tangutorum prepared in example 1.
Animals: KM mice.
Reagent: maltose, sucrose and acarbose, Solaibio; alpha-glucosidase (from yeast) and porcine pancreatic alpha-amylase, Megazyme, Ireland, glucose, Michelin Biochemical technology, Inc., P-NPG (4-Nitrophenyl glucopyranoside, purity > 98%), Sigma, USA; starch, guangzhou Tianjun Biotech limited.
An experimental instrument:
H1850R low temperature centrifuge (Hunan instrument centrifuge, Inc.), Epoch2 microplate reader (BioTek Inc.), BE9010 constant temperature oscillator (Haiman, Tubel instruments manufacture, Inc., Haimen), CTXNW-100B circulation ultrasonic extractor (Beijing Honghong biotech development, Inc.), N-1210BV-WB rotary evaporator (Shanghai Ailang instruments, Inc.), balance (Ahaouse instruments, Inc.), FDU-1100 freeze dryer (Erlangaki International (Shanghai) Inc.), PTA-125 pure water instrument (Tanto Si Tek, Inc.).
2. Research on drug effect of Tangut Nitraria tangutorum bobr extract on reduction of PGB (PGB) of diabetic mice
(1) Hypoglycemic effect of two kinds of Tanggute Nitraria tangutorum bobr extracts in normal mice
40 normal mice were divided into 4 groups of 10 mice each. The administration was carried out in the following manner, respectively:
control group (Control): intragastric purified water for each mouse;
positive control group (Acarbose): each mouse was gavaged with acarbose at 4 mg/kg;
test group 1 (BCST): 400mg/kg of the Tanggute Nitraria aqueous extract is infused into each mouse;
test group 2 (BCCT): each mouse had 400mg/kg of the ethanolic extract of Tanggute Nitraria.
After administration, each group of mice was individually gazed with 2g/kg of sucrose, and blood glucose levels were measured at 0, 30, 60, 90 and 120min after sucrose gavage, respectively (fig. 1A, 1C).
As a result, as shown in fig. 1A and 1C, the blood glucose level of the control group reached a peak at 30 minutes and then declined. The blood glucose levels were reduced in the 400mg/kg Tangut Nitraria extract and 4mg/kg acarbose group mice compared to the control group, but the differences between the three groups were not significant. Compared with a control group, the Tanggute nitraria aqueous extract group of 400mg/kg has no hypoglycemic activity. The results show that the tangut white spine alcohol extract has the capability of controlling the increase of the postprandial blood sugar level.
(2) Hypoglycemic effect of two kinds of Tanggute Nitraria tangutorum bobr extracts in normal mice
Construction of mouse model for diabetes mellitus Tetraoxopyrimidine induction was performed by the method of Zhao et al (Zhao, X.; Tao, J.; Zhang, T.; Jiang, S.; Wei, W.; Han, H.; Shao, Y.; Zhou, G.yue H.L.Resversatoside Alleviates Postprandial hypertriglyceridemia in diabetes mellitus Mice by comprehensive inhibition a-glucopyranosidase.J.aggregate.food m).
40 diabetic mice were divided into 4 groups of 10 mice each. The administration was carried out in the following manner, respectively:
control group (Control): intragastric purified water for each mouse;
positive control group (Acarbose): each mouse was gavaged with acarbose at 4 mg/kg;
test group 1 (BCST): 400mg/kg of the Tanggute Nitraria aqueous extract is infused into each mouse;
test group 2 (BCCT): each mouse had 400mg/kg of the ethanolic extract of Tanggute Nitraria.
After administration, the mice in each group were individually gazed with 2g/kg of sucrose, and blood glucose levels were measured at 0, 30, 60, 90 and 120min after sucrose gavage, respectively (fig. 1B, fig. 1D).
As shown in FIGS. 1B and 1D, the postprandial blood glucose levels of mice with 400mg/kg of Nitraria tangutorum bobr alcohol extract and 4mg/kg of acarbose group were significantly reduced (p <0.001) compared with the control group, while the postprandial blood glucose reduction of mice with 400mg/kg of Nitraria tangutorum bobr water extract group was insignificant compared with the control group. The results strongly demonstrate that the Nitraria tangutorum extract has the ability to lower the postprandial blood glucose level of mice.
3. Study on inhibitory activity of alpha-amylase and alpha-glucosidase in Nitraria tangutorum bobr extract
The inhibitory activities of the Nitraria tangutorum alcohol extract and the water extract on alpha-glucosidase (from yeast), sucrase (from rat small intestine), maltase (from rat small intestine) and alpha-amylase (from pig pancreas) were respectively studied by taking acarbose as a positive control.
(1) Study on the inhibitory activity of alpha-glucosidase, 50. mu.L of 1.25mg/mL was added to a 96-well plate under ice-bath conditions-1Sample of (2) and 50uL 0.5U mL-1The enzyme solution is put into a constant temperature oscillator at 37 ℃ for 100r min-1Incubate for 10min, add 50uL of 0.5mmol mL under ice bath-1Then putting the p-NPG into a constant temperature oscillator at 37 ℃, incubating for 20min at 100r/min, immediately putting into an ice water bath for 5min, reducing the enzyme activity, and continuously adding 0.1mol L-1Na2CO3The reaction was stopped with 50. mu.L of the solution. The detection was carried out at a wavelength of 409nm and the inhibitory activity of the sample on the enzyme was calculated.
(2) Sucrase and maltase inhibitory activity studies: alpha-glucosidase (maltase, EC 3.2.1.20; sucrase, EC 3.2.1.48) inhibitory activity screening: 50 μ L of the enzyme solution containing 17.5U/mL and 50 μ L of the 0.625mg/mL sample were added to a 48-well plate and preincubated at 37 ℃ for 10 min. Then, 50. mu.L of 0.5mol/L sucrose solution was added and the mixture was incubated at 37 ℃ for 20 min. Immediately putting into ice water bath for 5min, reducing enzyme activity, and continuously adding 0.1mol/LNa2CO3The reaction was stopped with 50uL of solution.And (3) determining the concentration of glucose by adopting a glucose kit, and calculating the inhibitory activity of the sample on the sucrase.
50. mu.L of an enzyme solution containing 11.56U/mL and 50. mu.L of a 0.625mg/mL sample were added to a 48-well plate and preincubated at 37 ℃ for 10 min. Then, 50. mu.L of a 1.39mmol/mL maltose solution was added and the mixture was incubated at 37 ℃ for 20 min. Immediately putting into ice water bath for 5min, reducing enzyme activity, and continuously adding 0.1mol/LNa2CO3The reaction was stopped with 50uL of solution. And (3) determining the glucose concentration by adopting a glucose kit, and calculating the inhibitory activity of the sample on maltase.
(3) Study of α -amylase inhibitory activity: under the ice bath condition, 50 mu L of 1mg/mL sample and 50 mu L of 10U/mL enzyme solution are added into a 96-well plate, then the 96-well plate is placed into a constant temperature oscillator at 37 ℃, the 100r/min incubation is carried out for 10min, then 50 mu L of 0.1% (w/v) starch is added under the ice bath condition, then the 37- ℃ constant temperature oscillator is placed, the 100r/min incubation is carried out for 20min, the ice water bath is immediately put into the plate for 5min, the enzyme activity is reduced, 100 mu L of DNS solution is continuously added, and the reaction is carried out for 5min at 100 ℃. After the temperature is reduced to the normal temperature, the detection is carried out at the wavelength of 540nm, and the inhibitory activity of the sample on the enzyme is calculated.
The tangut white thorn alcohol extract has the inhibition rate of 19.3 percent on alpha-glucosidase (from saccharomycetes) under the concentration of 1.25mg/mL, 58.4 percent on alpha-amylase (from porcine pancreas) under the concentration of 1.0mg/mL, and 98.6 percent and 93.1 percent on sucrase and maltase under the concentration of 0.625mg/mL respectively. While the inhibition rate of the Nitraria tangutorum bobr water extract on alpha-glucosidase is only 1.1% at the concentration of 1.25mg/mL, the inhibition rate on alpha-amylase is 93.2% at the concentration of 1.0mg/mL, and the inhibition rates on sucrase and maltase are 19.3% and 46.7% at the concentration of 0.625mg/mL respectively. IC of Nitraria tangutorum bobr extract on sucrase and maltase500.182mg/mL and 0.340mg/mL, respectively.
From the above results, it can be known that the Nitraria tangutorum bobr extract has strong sucrase and maltase inhibitory activity, while the Nitraria tangutorum bobr extract has significant alpha-amylase inhibitory activity, and the results are shown in Table 1 and FIGS. 2 to 4.
TABLE 1 Nitraria tangutorum extracts (mg/mL) inhibitory Activity against alpha-glucosidase and alpha-amylase from various sources
Example 4 Soft capsules for lowering blood glucose containing an alcohol extract of Nitraria tangutorum
Mixing 80 parts of the tangut Nitraria tangutorum bobr alcohol extract prepared in example 1, 10 parts of DHA and 10 parts of vitamin E, uniformly preparing a soft capsule content material, and then carrying out capsule pressing treatment on the soft capsule content material and the soft capsule shell material on a pressing device to prepare the tangut Nitraria tangutorum bobr alcohol extract soft capsule.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (8)
1. An application of Nitraria tangutorum bobr extract in preparing food, medicine or health product for inhibiting sucrase and maltase activity;
the preparation method of the Nitraria tangutorum bobr extract comprises the following steps:
crushing Nitraria tangutorum bobr, extracting with ethanol water solution with volume concentration of more than 90%, performing solid-liquid separation, removing precipitate, and drying the liquid part to obtain Nitraria tangutorum bobr ethanol extract;
the ratio of the mass of the Tangut white spine powder obtained after crushing to the volume of the ethanol water solution is 1 g: 5-10 mL.
2. Use according to claim 1, wherein the extraction is ultrasound extraction.
3. The application of claim 2, wherein the temperature of ultrasonic extraction is 30-45 ℃, the time of ultrasonic extraction is 1.5-3.5 h, and the frequency of ultrasonic extraction is 15-35 kHz.
4. The use according to claim 3, wherein the number of times of ultrasonic extraction is 1-3 times.
5. The use according to any one of claims 1 to 4, wherein the Nitraria tangutorum extract reduces postprandial blood glucose by inhibiting sucrase and maltase activity.
6. The use according to any one of claims 1 to 4, wherein the food, drug or health product is in the form of tablet, oral liquid, granule, injection, patch, paste, powder, suppository or capsule.
7. The use according to any one of claims 1 to 4, wherein the concentration of the Nitraria tangutorum alcohol extract in the food, the medicine or the health product is 0.1 to 99.9 percent by mass.
8. The use of claim 6, wherein the food, pharmaceutical or nutraceutical product further comprises an adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910665113.6A CN110279729B (en) | 2019-07-23 | 2019-07-23 | Application of Nitraria tangutorum bobr extract in preparation of food, medicine or health-care product for inhibiting activities of sucrase and maltase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910665113.6A CN110279729B (en) | 2019-07-23 | 2019-07-23 | Application of Nitraria tangutorum bobr extract in preparation of food, medicine or health-care product for inhibiting activities of sucrase and maltase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110279729A CN110279729A (en) | 2019-09-27 |
| CN110279729B true CN110279729B (en) | 2021-08-27 |
Family
ID=68023774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910665113.6A Active CN110279729B (en) | 2019-07-23 | 2019-07-23 | Application of Nitraria tangutorum bobr extract in preparation of food, medicine or health-care product for inhibiting activities of sucrase and maltase |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110279729B (en) |
-
2019
- 2019-07-23 CN CN201910665113.6A patent/CN110279729B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 响应面法优化唐古特白刺种子总黄酮超声提取工艺;胡娜等;《天然产物研究与开发》;20121231(第24期);第1844-1848页，尤其是第1844页摘要，左栏第1段，第1845页第1.3.1，2.1.1节 * |
| 青海柴达木盆地唐古特白刺果实的降血糖作用研究;索有瑞等;《食品科学》;20041231;第25卷(第7期);第164-167页，尤其是第164页摘要，第165页1.1节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110279729A (en) | 2019-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008528B (en) | Compound sea cucumber preparation and preparation method thereof | |
| CN108477612B (en) | Dendrobium nutrition powder containing dendrobium officinale purified extract and preparation method thereof | |
| CN109315574A (en) | A kind of mulberry leaf balsam pear pressed candy | |
| KR20160007728A (en) | Method for manufacturing garlic skin extract and food composition for preventing and alleviating diabetes prepared using the same | |
| CN109069562A (en) | Polysaccharide digests inhibitor | |
| CN107537028B (en) | Formula for simultaneously assisting in reducing blood sugar and blood pressure and preparation method thereof | |
| CN110279729B (en) | Application of Nitraria tangutorum bobr extract in preparation of food, medicine or health-care product for inhibiting activities of sucrase and maltase | |
| CN108567914B (en) | Traditional Chinese medicine preparation with sleep improving effect and preparation method and application thereof | |
| KR101094157B1 (en) | The health food for improvement of glucosuria using madisin-materials of plants | |
| KR20180079920A (en) | Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract | |
| CN108771690B (en) | A Balanophora japonica L extract with blood sugar or blood lipid reducing effect, and its preparation method and application | |
| CN113663043B (en) | Composition with alpha-glucosidase inhibition effect and preparation method and application thereof | |
| JP2009057319A (en) | alpha-GLUCOSIDASE INHIBITOR, METHOD FOR PRODUCING MATERIAL CONTAINING ERIODICTYOL-7-O-GLUCOSIDE, AND FOOD AND DRINK CONTAINING THE SAME | |
| CN110279732A (en) | Application of the Fructus Chebulae extract in the food, drug or health care product that preparation inhibits amylase and glucosidase activity | |
| CN102727593A (en) | New use of wild buckwheat rhizome and wild buckwheat rhizome extract in preparation of hypoglycemic medicine and healthcare food | |
| TW202128202A (en) | Use of cyclocarya paliurus extract for enhancing the expression level of fat loss gene, increasing basal metabolic rate, and/or suppressing fat accumulation | |
| CN104013696B (en) | A kind of plant drug composition of preventing and treating metabolism syndrome and its application | |
| KR101361846B1 (en) | Atural plant composition for modulate enzyme mrna relate to glucose metabolism in cell | |
| CN105796656A (en) | Cistanche tubulosa extract and preparation method thereof | |
| CN106344829A (en) | Traditional Chinese medicine composition and production method thereof | |
| CN110090243A (en) | A kind of Semen euryales extract for Postprandial glucose control, preparation method and application | |
| WO2010037255A1 (en) | The usage of ginseng and gynostemma pentaphyllum compound preparation in manufacture of medicaments with the effects of lipid regulation and blood-sugar regulation | |
| CN110269876A (en) | Application of the Rhodiola crenulata extract in the food, drug or health care product that preparation inhibits amylase and glucosidase activity | |
| CN110279731A (en) | A kind of application of Asiatic sweet leaf extract in the food, drug or health care product that preparation reduces blood glucose | |
| NL2027132B1 (en) | Use of a composition in preparing a product that inhibits α-glucosidase activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |